FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318786110> ?p ?o ?g. }

• W2318786110 endingPage "210" @default.
• W2318786110 startingPage "204" @default.
• W2318786110 abstract "Purpose of review Over the last several years, novel immunologic pathways pivotal in the development of the pathobiology of psoriasis and psoriatic arthritis (PsA) have been revealed. These discoveries catalyzed a search for new treatment targets resulting in many new therapies that are now available for patients with psoriatic disease. Recent findings Helper T cells that secrete interleukin-17 (TH17) along with CD8+ cells, innate lymphocyte cells, and gamma delta T cells are important in the pathogenesis of psoriasis and PsA. Recently, agents that target interleukin-17, the interleukin-17 receptor, and interleukin-23 (antip19) have been approved or are in clinical trials. Apremilast, a new oral agent, was approved for the treatment of psoriasis and PsA. Summary Secukinumab, an interleukin-17A antibody, has been approved for treatment of psoriasis and PsA in the United States. It is effective with a good safety profile. Ixekizumab, another anti-interleukin-17A antibody, is currently in clinical trials and brodalumab, an interleukin-17 receptor antagonist, was removed from clinical trials because of safety concerns despite demonstrated efficacy in psoriasis and PsA. Targeting interleukin-23 with antibodies to p19 is another approach with encouraging results in psoriasis. Apremilast, an oral agent, approved to treat psoriasis and PsA demonstrates moderate efficacy with an excellent safety record. The role of tofacitinib in psoriatic disease remains to be determined pending a safety review in psoriasis and completion of PsA trials." @default.
• W2318786110 created "2016-06-24" @default.
• W2318786110 creator A5020367519 @default.
• W2318786110 creator A5080337749 @default.
• W2318786110 date "2016-05-01" @default.
• W2318786110 modified "2023-09-28" @default.
• W2318786110 title "New therapies for psoriasis and psoriatic arthritis" @default.
• W2318786110 cites W1835490086 @default.
• W2318786110 cites W1855295630 @default.
• W2318786110 cites W1892175722 @default.
• W2318786110 cites W1893060336 @default.
• W2318786110 cites W1919283206 @default.
• W2318786110 cites W1935617463 @default.
• W2318786110 cites W1957267795 @default.
• W2318786110 cites W1981177225 @default.
• W2318786110 cites W1982598880 @default.
• W2318786110 cites W1996677952 @default.
• W2318786110 cites W2003425690 @default.
• W2318786110 cites W2003687140 @default.
• W2318786110 cites W2013395523 @default.
• W2318786110 cites W2015334425 @default.
• W2318786110 cites W2047677831 @default.
• W2318786110 cites W2053127888 @default.
• W2318786110 cites W2058968313 @default.
• W2318786110 cites W2064645845 @default.
• W2318786110 cites W2095712743 @default.
• W2318786110 cites W2099687194 @default.
• W2318786110 cites W2103524303 @default.
• W2318786110 cites W2103750969 @default.
• W2318786110 cites W2107432039 @default.
• W2318786110 cites W2142905097 @default.
• W2318786110 cites W2145834141 @default.
• W2318786110 cites W2153414586 @default.
• W2318786110 cites W2157378590 @default.
• W2318786110 cites W2166077573 @default.
• W2318786110 cites W2171889601 @default.
• W2318786110 cites W2181499040 @default.
• W2318786110 cites W2195835569 @default.
• W2318786110 cites W2266045195 @default.
• W2318786110 cites W2298524951 @default.
• W2318786110 cites W2326643498 @default.
• W2318786110 cites W4211077900 @default.
• W2318786110 cites W823422456 @default.
• W2318786110 doi "https://doi.org/10.1097/bor.0000000000000274" @default.
• W2318786110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5812682" @default.
• W2318786110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27022911" @default.
• W2318786110 hasPublicationYear "2016" @default.
• W2318786110 type Work @default.
• W2318786110 sameAs 2318786110 @default.
• W2318786110 citedByCount "60" @default.
• W2318786110 countsByYear W23187861102016 @default.
• W2318786110 countsByYear W23187861102017 @default.
• W2318786110 countsByYear W23187861102018 @default.
• W2318786110 countsByYear W23187861102019 @default.
• W2318786110 countsByYear W23187861102020 @default.
• W2318786110 countsByYear W23187861102021 @default.
• W2318786110 countsByYear W23187861102022 @default.
• W2318786110 countsByYear W23187861102023 @default.
• W2318786110 crossrefType "journal-article" @default.
• W2318786110 hasAuthorship W2318786110A5020367519 @default.
• W2318786110 hasAuthorship W2318786110A5080337749 @default.
• W2318786110 hasBestOaLocation W23187861102 @default.
• W2318786110 hasConcept C126322002 @default.
• W2318786110 hasConcept C16005928 @default.
• W2318786110 hasConcept C203014093 @default.
• W2318786110 hasConcept C2776260265 @default.
• W2318786110 hasConcept C2777575956 @default.
• W2318786110 hasConcept C2778886723 @default.
• W2318786110 hasConcept C2779745271 @default.
• W2318786110 hasConcept C2779786854 @default.
• W2318786110 hasConcept C2780564577 @default.
• W2318786110 hasConcept C2781427535 @default.
• W2318786110 hasConcept C535046627 @default.
• W2318786110 hasConcept C71924100 @default.
• W2318786110 hasConceptScore W2318786110C126322002 @default.
• W2318786110 hasConceptScore W2318786110C16005928 @default.
• W2318786110 hasConceptScore W2318786110C203014093 @default.
• W2318786110 hasConceptScore W2318786110C2776260265 @default.
• W2318786110 hasConceptScore W2318786110C2777575956 @default.
• W2318786110 hasConceptScore W2318786110C2778886723 @default.
• W2318786110 hasConceptScore W2318786110C2779745271 @default.
• W2318786110 hasConceptScore W2318786110C2779786854 @default.
• W2318786110 hasConceptScore W2318786110C2780564577 @default.
• W2318786110 hasConceptScore W2318786110C2781427535 @default.
• W2318786110 hasConceptScore W2318786110C535046627 @default.
• W2318786110 hasConceptScore W2318786110C71924100 @default.
• W2318786110 hasIssue "3" @default.
• W2318786110 hasLocation W23187861101 @default.
• W2318786110 hasLocation W23187861102 @default.
• W2318786110 hasLocation W23187861103 @default.
• W2318786110 hasLocation W23187861104 @default.
• W2318786110 hasOpenAccess W2318786110 @default.
• W2318786110 hasPrimaryLocation W23187861101 @default.
• W2318786110 hasRelatedWork W1987440872 @default.
• W2318786110 hasRelatedWork W2007444191 @default.
• W2318786110 hasRelatedWork W2155933643 @default.
• W2318786110 hasRelatedWork W2195057011 @default.
• W2318786110 hasRelatedWork W2318786110 @default.

• next